CIK 0001626971 · Non-accelerated filer<br>Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464670809
- Phone
- (650) 900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- S-3 Offering Registration Statement
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market buy See Remarks bought 20,000 shares at $0.79 ($15,800)
- 4 Open-market buy Chief Financial Officer bought 34,000 shares at an average $0.75 ($25,639)
- 4 Open-market buy President and CEO bought 60,000 shares at an average $0.75 ($44,827)
- 8-K/A Event Shareholder vote results
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 8-K Event Delisting notice
- 4 Open-market buy President and CEO bought 25,000 shares at $0.76 ($19,070)
- 4 Open-market buy President and CEO bought 20,000 shares at an average $0.81 ($16,253)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 9 of 30 · 584 filings